11.5
İskemik Kalp Hastalığı: Genel Bakış
İskemik kalp hastalığı, kalbe kan akışı azaldığında ortaya çıkar ve bu da oksijen ve besin eksikliğine neden olur. Kan akışının azalması veya engellen…
İskemik kalp hastalığı, kalbe giden kan akışı azaldığında veya tıkandığında ortaya çıkar. Bu, yetersiz oksijen ve besin dağıtımına yol açarak kalp kası hasarına veya işlev bozukluğuna neden olur.
Bu duruma öncelikle ateroskleroz, arter duvarları içinde yağ birikintilerinin veya plakların birikmesi neden olur.
Zamanla, bu plaklar arterleri sertleştirebilir ve daraltabilir, bu da kan akışını kısıtlayabilir.
Bazen, koroner arteri daha da tıkayan ve potansiyel olarak anjina, miyokard enfarktüsü, kalp yetmezliği veya ani kardiyak ölüme yol açan bir pıhtı oluşumunu tetikleyen bir plak yırtılabilir.
İskemik kalp hastalığı için risk faktörleri yaş, cinsiyet, aile öyküsü, sigara, yüksek tansiyon ve kolesterol, obezite, diyabet ve strestir.
Hastalık, yaşam tarzı değişiklikleri ve aspirin, ACE inhibitörleri, organik nitratlar ve β blokerler gibi ilaçlarla yönetilebilir.
Daha ciddi vakalarda, kalbe yeterli kan akışını sağlamak için anjiyoplasti veya baypas cerrahisi gibi invaziv prosedürlere ihtiyaç duyulabilir.
View the full transcript and gain access to JoVE Core videos
Q1: What causes ischemic heart disease?
Ischemic heart disease results from reduced or obstructed blood supply to the heart, causing insufficient oxygen and nutrient delivery. Atherosclerosis is the primary cause, involving accumulation of fatty deposits and plaques within arterial walls. Over time, these plaques harden and narrow arteries, restricting blood flow and potentially triggering clot formation that further obstructs coronary arteries.
Q2: What are the main complications of ischemic heart disease?
Ischemic heart disease can lead to serious complications including angina, myocardial infarction, heart failure, and sudden cardiac death. These complications occur when plaque ruptures and forms a clot that blocks the coronary artery, severely restricting blood flow to the heart muscle and causing damage or dysfunction.
Q3: Which risk factors increase susceptibility to ischemic heart disease?
Multiple risk factors contribute to ischemic heart disease development, including age, gender, family history, smoking, high blood pressure, elevated cholesterol, obesity, diabetes, and stress. These factors work together to increase the likelihood of atherosclerosis development and plaque formation within coronary arteries.
Q4: How are medications used to manage ischemic heart disease?
Medications such as aspirin, ACE inhibitors, organic nitrates, and beta-blockers help manage ischemic heart disease by reducing symptoms and preventing complications. Aspirin acts as an antiplatelet agent, while antianginal drugs like organic nitrates and beta-blockers improve blood flow and reduce cardiac workload, protecting heart tissue from ischemic damage.
Q5: When are invasive procedures necessary for ischemic heart disease?
Invasive procedures like angioplasty and bypass surgery become necessary in severe cases when lifestyle changes and medications cannot adequately restore blood flow. These procedures mechanically restore adequate blood supply to the heart muscle, preventing further damage and reducing the risk of myocardial infarction or sudden cardiac death.
Q6: What role do antiplatelet drugs play in ischemic heart disease treatment?
Antiplatelet drugs prevent clot formation by inhibiting platelet aggregation, reducing the risk of thrombosis in narrowed coronary arteries. These medications, including aspirin and antiplatelet drugs prostaglandin synthesis p2y12 and glycoprotein iib iiia inhibitors, are essential for preventing acute coronary events in patients with ischemic heart disease.
Q7: How do lifestyle modifications complement pharmacological treatment?
Lifestyle changes form the foundation of ischemic heart disease management alongside medications. Reducing smoking, controlling blood pressure and cholesterol, maintaining healthy weight, managing diabetes, and reducing stress help slow atherosclerosis progression and decrease overall cardiovascular risk, enhancing the effectiveness of pharmacological interventions.